Skip to main content
SpringerLink
Log in

Ceritinib not cost effective for NSCLC in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. anaplastic lymphoma kinase

Reference

  • Peng Y, et al. Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Advances in Therapy : 1 Oct 2019. Available from: URL: http://doi.org/10.1007/s12325-019-01103-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ceritinib not cost effective for NSCLC in China. PharmacoEcon Outcomes News 839, 12 (2019). https://doi.org/10.1007/s40274-019-6293-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6293-8

Search

Navigation